Loading
A phase 1/2 trial of TRK-950, Nivolumab in melanoma, run by Toray Industries, Inc, now recruiting.
A Study of TRK-950 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05423262 by Toray Industries, Inc, with 49 participants planned, started 2022-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950. Conditions listed: Solid Tumor, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/